Status:
UNKNOWN
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
Lead Sponsor:
Peking University People's Hospital
Conditions:
Stem Cell Transplant Complications
Relapse Leukemia
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
PHASE3
Brief Summary
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of trans...
Detailed Description
Patients enrolled in this study would receive decitabine 200mg·m-2·d-1 on day -12 and -11 pre-HSCT. The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was modified BU/...
Eligibility Criteria
Inclusion
- patients with relapsed acute leukemia
- patients with acute leukemia in the third（or more）complete remission (CR3) status
Exclusion
- pregnancy women
- uncontrolled severe infection
Key Trial Info
Start Date :
December 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT03799224
Start Date
December 1 2018
End Date
December 31 2023
Last Update
May 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology,Beijing
Beijing, Beijing Municipality, China, 100044